Analyzing Luminex (LMNX) and Its Rivals

Luminex (NASDAQ: LMNX) is one of 79 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare Luminex to similar companies based on the strength of its analyst recommendations, valuation, dividends, risk, institutional ownership, profitability and earnings.

Volatility and Risk

Luminex has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Luminex’s competitors have a beta of 1.22, suggesting that their average share price is 22% more volatile than the S&P 500.

Valuation & Earnings

This table compares Luminex and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Luminex $270.64 million $13.81 million 31.14
Luminex Competitors $2.14 billion $234.27 million -30.38

Luminex’s competitors have higher revenue and earnings than Luminex. Luminex is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Luminex and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Luminex 9.52% 6.01% 5.47%
Luminex Competitors -315.50% -23.22% -9.55%

Analyst Recommendations

This is a summary of current ratings and target prices for Luminex and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Luminex 1 3 0 0 1.75
Luminex Competitors 275 1889 3385 106 2.59

Luminex currently has a consensus price target of $19.33, suggesting a potential downside of 5.92%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.74%. Given Luminex’s higher probable upside, equities research analysts clearly believe Luminex is more favorable than its competitors.

Institutional & Insider Ownership

79.0% of Luminex shares are owned by institutional investors. Comparatively, 51.8% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 6.9% of Luminex shares are owned by company insiders. Comparatively, 18.2% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Dividends

Luminex pays an annual dividend of $0.24 per share and has a dividend yield of 1.2%. Luminex pays out 36.4% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.9% and pay out 26.2% of their earnings in the form of a dividend.

Summary

Luminex competitors beat Luminex on 8 of the 15 factors compared.

About Luminex

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

Receive News & Ratings for Luminex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply